文献速递脑血管病

脑出血后抗血小板治疗随机试验

Study of Antithrombotic Treatment After Intracerebral Haemorrhage-Antiplatelets: A Randomized Trial.
PubMed 文献 · Stroke · 2026-06-18

结果显示,启动抗血小板治疗组复发性症状性ICH为15%,避免组为3%;主要缺血事件分别为9%和20%。结论认为启动组复发性ICH数值上更多、缺血事件更少。

要点

  • 脑出血后启动抗血小板治疗复发性ICH数值更高(15% vs 3%)。
  • 启动抗血小板治疗主要缺血事件数值更低(9% vs 20%)。

核心结论

  • 脑出血后启动抗血小板治疗的患者复发性ICH数值上更多,缺血事件数值上更少。

研究设计与样本

  • STATICH抗血小板试验为随机、多中心、开放、盲法终点平行组试验,目标样本量500例。
  • 纳入有抗血小板治疗指征的成人,1:1随机分配至启动或避免抗血小板治疗,随访至少2年。

主要发现

  • 启动抗血小板治疗组5例(15% [95% CI,6%-31%])发生复发性ICH,避免组1例(3% [95% CI,0%-18%])。
  • 启动组3例(9% [95% CI,3%-24%])发生主要缺血事件,避免组7例(20% [95% CI,10%-37%])。
  • 共登记88例严重不良事件,未发生可疑非预期严重不良反应。

关键数值与推荐

  • 启动抗血小板治疗组复发性症状性ICH为15%(95% CI,6%-31%),避免组为3%(95% CI,0%-18%)。
  • 启动组主要缺血事件为9%(95% CI,3%-24%),避免组为20%(95% CI,10%-37%)。

临床怎么用

  • 脑出血后是否启动抗血小板治疗需权衡复发性出血与缺血风险,当前证据不足以给出明确推荐。
  • 临床决策应结合患者个体出血与缺血风险,并关注后续个体患者数据Meta分析结果。

局限性

  • 开放设计,参与者未设盲,仅终点评估盲法。
  • 结果数值不一致但置信区间宽,统计效能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients surviving spontaneous intracerebral hemorrhage (ICH) who have indications for antithrombotic treatment face increased risks of both hemorrhagic and ischemic events. The aim of STATICH (Study of Antithrombotic Treatment After Intracerebral Haemorrhage) was to assess the safety and efficacy of long-term antithrombotic treatment after ICH. METHODS: STATICH Antiplatelets (EudraCT 2014-002636-13; Unique identifier: NCT03186729) was a randomized, multicenter, open, blinded end point parallel-group trial, including adults with an indication for antiplatelet treatment to either start or avoid antiplatelet treatment. The target sample size was 500 participants. Patients were allocated 1:1 by a Web-based randomization system and followed for a minimum of 2 years. Outcome assessments were done by personnel blinded to treatment. Participants were not blinded. The primary safety outcome was recurrent symptomatic ICH. RESULTS: The trial was stopped early due to slow recruitment. Sixty-nine patients were included between August 2018 and December 2022: 34 were randomized to start antiplatelet treatment, and 35 were randomized to avoid antiplatelet treatment. No patients were excluded from analyses. The median age was 75 (Q1-Q3, 66-80) years, and 43 (75%) had previous ischemic stroke or transient ischemic attack. Five patients in the start antiplatelet treatment group (15% [95% CI, 6%-31%]), and 1 in the avoid group (3% [95% CI, 0%-18%]) experienced recurrent ICH, while 3 (9% [95% CI, 3%-24%]) and 7 (20% [95% CI, 10%-37%]), respectively, experienced a major ischemic event. A total of 88 serious adverse events and no suspected unexpected serious adverse reactions were registered. CONCLUSIONS: There were numerically more recurrent ICHs and fewer ischemic events in patients starting antiplatelet treatment after ICH compared with those avoiding antiplatelet treatment. The slow recruitment might be due to clinicians being certain of the best treatment strategy or patients being too frail to participate. STATICH will contribute to a planned collaborative individual patient-data meta-analysis to resolve this dilemma.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Eilertsen H, Larsen KT, Forfang E, et al. Study of Antithrombotic Treatment After Intracerebral Haemorrhage-Antiplatelets: A Randomized Trial. Stroke. 2026. PMID: 42312355. doi:10.1161/STROKEAHA.125.054990

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。